ERBB2 and breast cancer: The Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (HER2), and Ki67 antigen are the four biomarkers routinely examined in BC biopsies and excision specimens due to their potential impact on heterogeneity prognosis and clinical therapy.